Page 160 - Read Online

Grewal et al. Art Int Surg 2023;3:217-32 https://dx.doi.org/10.20517/ais.2023.28 Page 227

Performed data acquisition, as well as providing administrative, technical, and material support: Grewal M,
Ahmed T, Javed AA

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol
2019;10:10-27. DOI PubMed PMC
2. Bridgewater J, Lopes A, Wasan H, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Ann Oncol 2016;27:134-40. DOI
3. Huang L, Jansen L, Balavarca Y, et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in
the early twenty-first century: a large, international population-based study. BMC Med 2018;16:125. DOI PubMed PMC
4. Brar G, Greten TF, Graubard BI, et al. Hepatocellular carcinoma survival by etiology: a SEER-medicare database analysis. Hepatol
Commun 2020;4:1541-51. DOI PubMed PMC
5. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6.
DOI PubMed PMC
6. Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol 2018;24:2047-60. DOI
PubMed PMC
7. Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. DOI PubMed PMC
8. Kennedy T, Preczewski L, Stocker SJ, et al. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for
clinically suspected carcinoma: a single-institution experience. Am J Surg 2006;191:437-41. DOI
9. Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response
assessment. Cells 2020;9:1370. DOI PubMed PMC
10. Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology
2019;156:2024-40. DOI PubMed PMC
11. Buchs NC, Chilcott M, Poletti PA, Buhler LH, Morel P. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative
diagnosis and surgical management. World J Gastroenterol 2010;16:818-31. PubMed PMC
12. Rehders A, Stoecklein NH, Güray A, Riediger R, Alexander A, Knoefel WT. Vascular invasion in pancreatic cancer: tumor biology
or tumor topography? Surgery 2012;152:S143-51. DOI
13. Dayimu A, Di Lisio L, Anand S, et al. Clinical and biological markers predictive of treatment response associated with metastatic
pancreatic adenocarcinoma. Br J Cancer 2023;128:1672-80. DOI PubMed PMC
14. Sturm N, Ettrich TJ, Perkhofer L. The impact of biomarkers in pancreatic ductal adenocarcinoma on diagnosis, surveillance and
therapy. Cancers 2022;14:217. DOI PubMed PMC
15. Zhang WH, Wang WQ, Han X, et al. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: a systems biology
perspective. Comput Struct Biotechnol J 2020;18:3606-14. DOI PubMed PMC
16. Herreros-Villanueva M, Bujanda L. Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Ann
Transl Med 2016;4:134. DOI PubMed PMC
17. Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in hepatobiliary cancers: what is useful in clinical